Pasithea Therapeutics (KTTA) Competitors $3.16 -0.03 (-0.94%) (As of 02:30 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends KTTA vs. VCNX, RNAZ, APRE, MTEX, INAB, TXMD, NERV, AKTX, NRXP, and KZIAShould you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include Vaccinex (VCNX), TransCode Therapeutics (RNAZ), Aprea Therapeutics (APRE), Mannatech (MTEX), IN8bio (INAB), TherapeuticsMD (TXMD), Minerva Neurosciences (NERV), Akari Therapeutics (AKTX), NRx Pharmaceuticals (NRXP), and Kazia Therapeutics (KZIA). These companies are all part of the "pharmaceutical products" industry. Pasithea Therapeutics vs. Vaccinex TransCode Therapeutics Aprea Therapeutics Mannatech IN8bio TherapeuticsMD Minerva Neurosciences Akari Therapeutics NRx Pharmaceuticals Kazia Therapeutics Pasithea Therapeutics (NASDAQ:KTTA) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation, earnings and community ranking. Which has more volatility and risk, KTTA or VCNX? Pasithea Therapeutics has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Vaccinex has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Which has higher valuation and earnings, KTTA or VCNX? Pasithea Therapeutics has higher earnings, but lower revenue than Vaccinex. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPasithea Therapeutics$20K200.66-$15.96MN/AN/AVaccinex$570K10.74-$20.25M-$48.27-0.07 Do institutionals and insiders hold more shares of KTTA or VCNX? 23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 50.1% of Vaccinex shares are held by institutional investors. 16.3% of Pasithea Therapeutics shares are held by insiders. Comparatively, 51.5% of Vaccinex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community favor KTTA or VCNX? Vaccinex received 121 more outperform votes than Pasithea Therapeutics when rated by MarketBeat users. Likewise, 60.00% of users gave Vaccinex an outperform vote while only 40.00% of users gave Pasithea Therapeutics an outperform vote. CompanyUnderperformOutperformPasithea TherapeuticsOutperform Votes240.00% Underperform Votes360.00% VaccinexOutperform Votes12360.00% Underperform Votes8240.00% Does the media favor KTTA or VCNX? In the previous week, Pasithea Therapeutics had 2 more articles in the media than Vaccinex. MarketBeat recorded 4 mentions for Pasithea Therapeutics and 2 mentions for Vaccinex. Pasithea Therapeutics' average media sentiment score of 0.76 beat Vaccinex's score of 0.67 indicating that Pasithea Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pasithea Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaccinex 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is KTTA or VCNX more profitable? Vaccinex's return on equity of 0.00% beat Pasithea Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Pasithea TherapeuticsN/A -81.57% -74.31% Vaccinex N/A N/A -383.58% SummaryVaccinex beats Pasithea Therapeutics on 7 of the 12 factors compared between the two stocks. Ad Brownstone ResearchBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.I believe we are about to do it again with this new AI project called Stargate Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KTTA vs. The Competition Export to ExcelMetricPasithea TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.01M$6.53B$5.10B$8.84BDividend YieldN/A8.11%5.04%4.07%P/E RatioN/A5.5095.1214.22Price / Sales200.66375.021,217.3088.42Price / CashN/A52.5939.4936.27Price / Book0.2210.276.976.37Net Income-$15.96M$153.22M$118.73M$225.56M7 Day Performance-4.24%-1.19%-1.22%-0.02%1 Month Performance-28.02%-6.71%-3.07%2.04%1 Year Performance-50.93%32.39%32.52%28.00% Pasithea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KTTAPasithea Therapeutics1.3273 of 5 stars$3.16-0.9%N/A-50.4%$4.01M$20,000.000.003News CoverageGap DownVCNXVaccinex0.5972 of 5 stars$3.54-4.6%N/A-70.2%$6.12M$570,000.00-0.0740RNAZTransCode Therapeutics2.651 of 5 stars$0.38+12.4%$3.00+693.7%-96.3%$6.53MN/A0.009APREAprea Therapeutics3.3831 of 5 stars$2.92-3.0%$15.50+430.8%-22.4%$15.86M$580,000.000.007Analyst ForecastAnalyst RevisionGap DownMTEXMannatech0.936 of 5 stars$8.40+4.3%N/A-15.5%$15.79M$131.96M0.00250Analyst ForecastGap UpHigh Trading VolumeINABIN8bio2.7424 of 5 stars$0.33+3.6%$7.75+2,227.3%-62.8%$15.58MN/A0.0020TXMDTherapeuticsMD0.6657 of 5 stars$1.34flatN/A-54.1%$15.45M$1.30M0.00420Analyst ForecastNERVMinerva Neurosciences2.3494 of 5 stars$2.21+4.2%$5.00+126.2%-57.1%$15.45MN/A-4.829Analyst ForecastAKTXAkari TherapeuticsN/A$1.25-15.0%N/A-55.0%$15.19MN/A0.009Analyst ForecastNews CoverageHigh Trading VolumeNRXPNRx Pharmaceuticals1.9932 of 5 stars$1.23+1.4%$31.50+2,467.2%-96.1%$14.83MN/A0.002KZIAKazia Therapeutics1.8779 of 5 stars$5.37-4.3%$20.00+272.4%-26.9%$14.18M$1.51M0.0012 Related Companies and Tools Related Companies Vaccinex Alternatives TransCode Therapeutics Alternatives Aprea Therapeutics Alternatives Mannatech Alternatives IN8bio Alternatives TherapeuticsMD Alternatives Minerva Neurosciences Alternatives Akari Therapeutics Alternatives NRx Pharmaceuticals Alternatives Kazia Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KTTA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
